- An innovative treatment called lifileucel, which uses a patient's own immune system to combat advanced melanoma, has shown promising results in extending the lives of patients, according to researchers.
- In a trial led by The Royal Marsden NHS Foundation Trust involving 153 patients, almost 20 per cent of those with advanced melanoma survived for five years after receiving lifileucel, with the majority experiencing tumour shrinkage.
- Experts suggest lifileucel could be a transformative option for patients with advanced melanoma, where the cancer has spread to other parts of the body.
- The treatment involves isolating and growing T cells from tumours in a lab before infusing them back into the patient to fight cancer, and it has already been approved by the US Food and Drug Administration (FDA) for advanced melanoma treatment.
- Zoe Phillips, a participant in the TIL therapy trial, experienced complete remission of her tumours six weeks after treatment, highlighting the potential of this therapy for patients with limited options.
IN FULL
‘Transformative’ one-time therapy could help skin cancer patients live longer
